Featured presentations showcase the positive Phase 1 healthy volunteer trial results supporting KT-621’s oral, dupilumab-like profile KT-621 BroADen Phase 1b trial in moderate to severe atopic dermatitis (AD) patients on track to report data in 4Q25 KT-621 Phase 2b trials in AD and asthma on track to initiate in 4Q25 and 1Q26, respectively WATERTOWN, Mass., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral sm ...

Core Insights - Kymera Therapeutics reported positive Phase 1 data for KT-621, a once-daily oral STAT6 degrader, which exceeded the company's target product profile and demonstrated a safety profile similar to placebo [1][2][3] - The company is on track to report data from the KT-621 BroADen Phase 1b trial in moderate to severe atopic dermatitis (AD) patients in Q4 2025, with Phase 2b trials in AD and asthma set to begin in Q4 2025 and Q1 2026, respectively [1][2][7] - Kymera has entered a strategic partnership with Gilead to develop CDK2 degraders, with potential total payments of up to $750 million [1][9] - As of July 31, 2025, the company had $1 billion in cash, providing a runway into the second half of 2028 [1][10] Business Highlights - KT-621 demonstrated over 90% mean STAT6 degradation at doses above 1.5 mg, with complete degradation at doses ≥50 mg [3][4] - The drug showed median reductions in Th2 biomarkers, with TARC reduction up to 37% and Eotaxin-3 reduction up to 63% [4] - KT-579, an oral IRF5 degrader, is expected to enter Phase 1 clinical trials in early 2026, showing promise in treating lupus and rheumatoid arthritis [5][8] Collaboration Updates - The partnership with Gilead includes an exclusive option and license agreement for the CDK2 program, with Kymera leading research activities [6][9] - Sanofi plans to advance KT-485, a second-generation IRAK4 degrader, into clinical studies, while Kymera achieved a $20 million milestone related to KT-485 [9] Financial Results - Collaboration revenues for Q2 2025 were $11.5 million, down from $25.7 million in Q2 2024, primarily due to the recognition of deferred revenue from the Sanofi collaboration [11] - Research and development expenses increased to $78.4 million in Q2 2025 from $59.2 million in Q2 2024, driven by investments in the STAT6 program [12] - The net loss for Q2 2025 was $76.6 million, compared to $42.1 million in Q2 2024 [14]

Core Insights - Kymera Therapeutics is advancing its first-in-class pipeline aimed at treating complex immuno-inflammatory diseases, with significant progress expected in the near term [2] - The company has completed the Phase 1 healthy volunteer trial for KT-621 and initiated the KT-621 BroADen Phase 1b trial in atopic dermatitis, with data expected in late 2025 [1][2][7] - Kymera has introduced KT-579, an oral IRF5 degrader program, which is set to enter Phase 1 clinical trials in early 2026 [1][4] - A strategic decision was made to not advance KT-295 into further clinical development, allowing for a focus on the STAT6 program and extending the cash runway into the first half of 2028 [1][2][16] Business Highlights - The KT-621 program targets Th2 inflammation and has shown dupilumab-like activity in preclinical studies, with potential applications for over 130 million patients globally suffering from Th2 diseases [3] - KT-579 is positioned as a novel mechanism for treating diseases with high unmet needs, such as lupus and rheumatoid arthritis, and is expected to enter clinical testing in early 2026 [4] - Ongoing Phase 2b trials for KT-474 in partnership with Sanofi are expected to complete in 2026, further validating Kymera's innovative approach to oral degrader medicines [8] Financial Results - Collaboration revenues for Q1 2025 were $22.1 million, a significant increase from $10.3 million in Q1 2024, primarily due to the Sanofi collaboration [9] - Research and development expenses rose to $80.3 million in Q1 2025 from $48.8 million in Q1 2024, reflecting increased investment in the STAT6 and TYK2 programs [10] - The net loss for Q1 2025 was $65.6 million, compared to $48.6 million in Q1 2024, with cash reserves of $775 million expected to sustain operations into the first half of 2028 [12][22]

Core Insights - Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing oral small molecule degrader medicines for immunological diseases [1][3] - The company will participate in a fireside chat at the BofA Securities 2025 Healthcare Conference on May 14, 2025 [1] - A live webcast of the presentation will be available on the company's website, with a replay archived post-event [2] Company Overview - Kymera Therapeutics is pioneering targeted protein degradation (TPD) to create medicines for critical health issues, aiming to improve patient outcomes significantly [3] - The company has advanced its first degrader into clinical trials for immunological diseases and is building a robust pipeline of oral small molecule degraders [3] - Founded in 2016, Kymera has been recognized as one of Boston's top workplaces in recent years [3] Communication and Information Availability - Kymera encourages investors and the public to review information posted on its website and social media platforms, which may contain material information [4] - The company utilizes its website for corporate disclosures, investor presentations, SEC filings, and press releases [4]